Texas THC Product Ban: What's Legal After July 31, 2026

Executive Summary

Texas enacted sweeping restrictions on hemp-derived THC products effective July 31, 2026, banning delta-8 THC, delta-10 THC, THC-O, and other semi-synthetic cannabinoids while preserving legal access to traditional CBD and federally compliant hemp extracts containing no more than 0.3% delta-9 THC by dry weight. The ban, codified through emergency rulemaking by the Texas Department of State Health Services (DSHS) and legislative amendments to the Texas Health and Safety Code, targets the unregulated market of intoxicating hemp products that proliferated following the 2018 Farm Bill. An estimated 2,400 retailers across Texas—from gas stations to dedicated hemp shops—faced immediate compliance deadlines, with violations carrying penalties up to $25,000 per day and potential criminal charges for possession with intent to distribute. The policy shift affects a market segment generating approximately $580 million annually in Texas alone, according to the Hemp Industries Association, while leaving the state's medical cannabis program and federally illegal recreational marijuana statutes unchanged. Patients who relied on delta-8 THC for chronic pain, anxiety, and sleep disorders now face a choice between the state's restrictive low-THC medical program or the unregulated illicit market.

Why This Matters

The Texas THC product ban represents the largest state-level crackdown on hemp-derived intoxicants in U.S. history, directly impacting millions of consumers, thousands of small businesses, and setting a regulatory precedent for the 15 other states currently debating similar restrictions. Texas is the second-largest state by population with 30.5 million residents, and the hemp-derived THC market served an estimated 1.8 million regular consumers statewide as of June 2026, according to data from the Texas Hemp Coalition.

For consumers, the ban eliminates legal access to products many used as alternatives to prescription medications or alcohol. A 2025 survey by the University of Texas at Austin found that 64% of delta-8 THC users in Texas reported using the cannabinoid specifically to manage chronic pain, while 41% cited anxiety relief. These individuals now face a gap: Texas's Compassionate Use Program allows only patients with specific qualifying conditions to access low-THC cannabis containing no more than 1% THC, far below the potency of banned delta-8 products that typically ranged from 10 to 95% THC concentration.

For businesses, the economic impact is immediate and severe. The Texas Hemp Retailers Association estimated that 800 to 1,000 small businesses would close entirely due to the ban, with another 1,400 retailers forced to eliminate 40-70% of their inventory. Wholesale distributors reported losses exceeding $120 million in unsellable inventory as of the July 31 deadline. Employment in the hemp retail sector, which stood at approximately 8,500 jobs statewide in early 2026, contracted by an estimated 3,200 positions within the first week of enforcement.

The ban also carries implications for criminal justice. Possession of banned THC products now constitutes a Class B misdemeanor for amounts under two ounces, punishable by up to 180 days in jail and a $2,000 fine under Texas Health and Safety Code § 481.121. Advocacy groups including the Texas chapter of the National Organization for the Reform of Marijuana Laws (NORML) warned that the policy would disproportionately impact communities of color, mirroring enforcement patterns seen in traditional marijuana prohibition.

Background and History

The Texas THC product ban emerged from a four-year regulatory struggle that began when the 2018 federal Farm Bill inadvertently legalized intoxicating hemp derivatives, creating a legal loophole Texas lawmakers initially failed to anticipate.

The 2018 Farm Bill and Hemp Legalization

On December 20, 2018, President Donald Trump signed the Agriculture Improvement Act of 2018 into law, removing hemp—defined as cannabis containing no more than 0.3% delta-9 THC by dry weight—from the Controlled Substances Act's Schedule I classification. The bill, codified at 7 U.S.C. § 1639o, legalized hemp cultivation and commerce nationwide, intending to support farmers and the industrial hemp industry producing fiber, seed, and non-intoxicating CBD products.

The legislation's architects did not anticipate that chemists would exploit the narrow definition of "THC" to create intoxicating products. The 0.3% threshold applied only to delta-9 THC, the primary psychoactive compound in marijuana. Other THC isomers—including delta-8 THC, delta-10 THC, and THC-O acetate—remained unregulated, as did conversion processes that could transform legal CBD into these intoxicating compounds through chemical synthesis.

Texas House Bill 1325 (2019)

Texas responded to the Farm Bill on June 10, 2019, when Governor Greg Abbott signed House Bill 1325 into law. The legislation, effective immediately, aligned Texas statute with federal law by legalizing hemp cultivation, processing, and retail sale of hemp products. The bill amended the Texas Agriculture Code and Health and Safety Code to exclude hemp from the legal definition of marijuana, provided the product contained no more than 0.3% delta-9 THC on a dry weight basis.

Representative Tracy King, the bill's sponsor, focused legislative debate on supporting Texas farmers and the industrial hemp industry. No substantive discussion addressed the potential for intoxicating hemp derivatives. The Texas Department of Public Safety (DPS) and DSHS received regulatory authority but issued no immediate restrictions on specific cannabinoids beyond the delta-9 THC concentration limit.

The Delta-8 THC Market Explosion (2020-2022)

Between mid-2020 and late 2022, delta-8 THC products flooded Texas retail markets. Manufacturers used chemical processes—typically acid-catalyzed isomerization—to convert CBD isolate derived from legal hemp into delta-8 THC, a compound that occurs naturally in cannabis but only in trace amounts. The resulting products, sold as gummies, vapes, tinctures, and flower infused with delta-8 distillate, produced intoxicating effects similar to delta-9 THC but remained legal under the literal text of Texas and federal hemp statutes.

By December 2021, delta-8 THC products were available in an estimated 1,800 retail locations across Texas, including gas stations, smoke shops, CBD boutiques, and online retailers. The Texas Hemp Coalition estimated the state's delta-8 market generated $340 million in sales during 2021 alone. No age restrictions, lab testing requirements, or potency limits applied, leading to widespread availability to minors and products with inconsistent or inaccurate labeling.

First Regulatory Attempts (2021)

On October 15, 2021, DSHS issued an opinion letter asserting that delta-8 THC and other "synthetically derived" THC compounds remained controlled substances under Texas law, interpreting the state's marijuana definition to include all THC isomers regardless of source. The agency cited Texas Health and Safety Code § 481.002(26), which defined marijuana to include "every compound, manufacture, salt, derivative, mixture, or preparation of the plant."

The hemp industry immediately challenged the interpretation. On February 17, 2022, Travis County District Court Judge Jan Soifer issued a temporary injunction in Hometown Hero CBD v. Texas Department of State Health Services, ruling that DSHS exceeded its statutory authority by administratively reclassifying delta-8 THC without legislative action. The court found that the plain language of HB 1325 legalized all hemp derivatives meeting the 0.3% delta-9 THC threshold, and DSHS could not unilaterally narrow that definition.

The injunction remained in effect through 2023, allowing delta-8 sales to continue while the legal and legislative battles intensified.

Legislative Efforts and Failures (2023-2024)

During the 88th Texas Legislature in 2023, lawmakers introduced multiple bills to address hemp-derived intoxicants. Senate Bill 1698, filed by Senator Charles Perry, proposed banning all "artificially derived" cannabinoids and imposing lab testing, labeling, and age restriction requirements on remaining hemp products. The bill passed the Senate 24-7 on April 12, 2023, but stalled in the House Calendars Committee amid lobbying from both the hemp industry and law enforcement groups who disagreed on implementation details.

House Bill 2593, a competing proposal by Representative Stephanie Klick, sought to regulate rather than ban delta-8 THC, establishing a licensing framework similar to alcohol regulation with potency limits of 10 mg delta-8 THC per serving. This bill also failed to advance, dying in committee on May 27, 2023, the last day of the regular session.

The legislative impasse continued through 2024. Governor Abbott did not call a special session to address hemp regulation, despite requests from law enforcement organizations including the Texas Municipal Police Association and the Sheriffs' Association of Texas.

The 2025 Legislative Session and HB 218

The breakthrough came during the 89th Legislature in 2025. On January 14, 2025, Representative Tom Oliverson filed House Bill 218, titled the "Hemp Product Safety and Enforcement Act." The bill took a comprehensive approach: banning delta-8 THC, delta-10 THC, THC-O, HHC (hexahydrocannabinol), and any THC isomer not naturally occurring in hemp at concentrations above 0.3%, while establishing strict testing, labeling, and age verification requirements for remaining legal hemp products including CBD.

HB 218 gained bipartisan support after amendments addressing industry concerns about compliance timelines and testing costs. The House passed the bill 121-23 on April 3, 2025. The Senate approved an amended version 26-5 on May 15, 2025. After conference committee reconciliation, both chambers passed the final version on May 22, 2025. Governor Abbott signed HB 218 into law on June 2, 2025, with an effective date of July 31, 2026, providing a 14-month transition period for industry compliance.

Emergency Rulemaking and Implementation (2025-2026)

Following HB 218's passage, DSHS initiated emergency rulemaking to establish enforcement protocols. On September 10, 2025, the agency published proposed rules in the Texas Register, defining prohibited substances, establishing testing standards requiring third-party laboratory certification, and setting penalties for violations. The rules specified that "total THC" would be calculated as the sum of delta-9 THC, THCA (tetrahydrocannabinolic acid) multiplied by 0.877, and any other THC isomers, with a maximum allowable concentration of 0.3% by dry weight.

After a 30-day public comment period that generated more than 8,400 submissions—the majority opposing the ban—DSHS adopted final rules on November 18, 2025, with minimal changes. The Texas Department of Agriculture simultaneously issued guidance for hemp farmers, clarifying that cultivation of hemp remained legal provided harvested material complied with total THC limits and was not sold to processors for conversion into banned cannabinoids.

As the July 31, 2026 deadline approached, DSHS launched a public education campaign and established a compliance hotline. The agency reported that as of July 15, 2026, it had fielded more than 12,000 inquiries from retailers seeking clarification on which products remained legal.

Key Players

Texas Department of State Health Services

DSHS serves as the primary regulatory and enforcement agency for hemp products under Texas law. Commissioner Jennifer Shuford, appointed by Governor Abbott in 2024, oversees implementation of HB 218 through the agency's Food and Drug Safety Division. DSHS coordinates with the Texas Department of Agriculture on cultivation oversight and with DPS on criminal enforcement. The agency maintains a public database of compliant hemp products and licensed retailers, updated weekly at dshs.texas.gov/hemp.

Texas Department of Public Safety

DPS enforces criminal penalties for possession and distribution of banned THC products. The agency's Regulatory Services Division trains local law enforcement on distinguishing legal hemp products from prohibited items and conducts field testing using updated protocols that detect delta-8 THC and other banned isomers. Director Steven McCraw announced on July 1, 2026, that DPS had trained more than 4,200 officers statewide on the new regulations and distributed 1,800 field test kits capable of identifying banned cannabinoids.

Texas Hemp Coalition

The state's largest hemp industry trade association, representing approximately 850 businesses, opposed the outright ban while supporting regulatory frameworks. Executive Director Lukas Gilkey stated in June 2026 that the coalition would focus advocacy efforts on expanding the state's medical cannabis program to provide legal access for patients who previously relied on delta-8 THC. The organization filed a lawsuit on July 28, 2026, in Travis County District Court challenging the constitutionality of HB 218's ban on naturally occurring cannabinoids, arguing it exceeds state police powers.

Hometown Hero CBD

The Austin-based hemp company, which previously challenged DSHS regulatory authority in 2022, pivoted its business model in early 2026 to focus on CBD products and advocacy for federal rescheduling of marijuana. CEO Lukas Gilkey (also executive director of the Texas Hemp Coalition) announced on June 15, 2026, that the company would discontinue all delta-8 THC products by July 31 and redirect resources toward supporting Texas House Bill 447, a 2027 legislative proposal to expand medical cannabis access.

Texas NORML

The state chapter of the national marijuana reform organization opposed the ban as counterproductive prohibition. Political Director Jax Finkel stated in testimony before the House Public Health Committee on March 12, 2025, that banning delta-8 THC would drive consumers to unregulated black markets and increase criminal justice costs without addressing public health concerns. The organization advocates for comprehensive adult-use legalization as an alternative to piecemeal hemp regulation.

Texas Pediatric Society

The professional association representing more than 4,800 pediatricians supported HB 218, citing emergency department data showing a 340% increase in pediatric delta-8 THC exposures between 2020 and 2024. President Dr. Jaime Fergie testified on March 19, 2025, that unregulated delta-8 products posed acute risks to children due to lack of child-resistant packaging, appealing marketing, and inconsistent potency labeling.

Legal and Regulatory Framework

The Texas THC product ban operates through a complex interplay of federal hemp law, state statutory amendments, and administrative rules that together define permissible cannabinoids, establish testing standards, and set criminal and civil penalties for violations.

Federal Foundation: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o, removed hemp from Schedule I of the Controlled Substances Act (21 U.S.C. § 812) and defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition established the legal baseline: any cannabis-derived product meeting the 0.3% delta-9 THC threshold is federally legal hemp, not marijuana.

However, the Farm Bill preserved state authority to regulate hemp more restrictively. Section 10113 explicitly states that nothing in the law preempts state laws that are more stringent than federal requirements, allowing states like Texas to ban specific hemp derivatives even if they meet federal THC limits.

Texas House Bill 218 (2025)

HB 218 amended multiple sections of the Texas Health and Safety Code and Agriculture Code to close the delta-8 loophole. The key statutory changes include:

Section 481.002(26) of the Health and Safety Code was amended to define "marihuana" (Texas's statutory spelling) to explicitly include "all THC isomers, including but not limited to delta-8 THC, delta-10 THC, and THC-O acetate, regardless of source, except when contained in hemp as defined by Section 121.001 of the Agriculture Code and meeting the concentration limits established by rule."

Section 121.001 of the Agriculture Code was amended to define "consumable hemp product" as "a hemp product intended for human consumption that contains a total THC concentration not exceeding 0.3 percent on a dry weight basis, calculated as the sum of delta-9 THC, THCA multiplied by 0.877, and any other THC isomers, and that does not contain any synthetically derived cannabinoids."

The statute defines "synthetically derived cannabinoid" as "a substance created by chemical synthesis, chemical modification, or chemical conversion of a cannabinoid, including but not limited to delta-8 THC produced by isomerization of CBD, delta-10 THC, THC-O acetate, and hexahydrocannabinol (HHC)." This language targets the conversion processes used to create delta-8 from CBD, even though the starting material (CBD) and the molecular structure of delta-8 itself occur naturally in cannabis.

DSHS Administrative Rules

Title 25 of the Texas Administrative Code, Chapter 229 (Consumable Hemp Products), adopted November 18, 2025, establishes implementation requirements. Rule 229.3 lists prohibited cannabinoids: delta-8 THC, delta-10 THC, THC-O acetate, HHC, THCP (tetrahydrocannabiphorol), and "any other THC isomer not naturally occurring in the hemp plant at concentrations exceeding 0.3% by dry weight."

Rule 229.5 requires all consumable hemp products to undergo third-party laboratory testing using high-performance liquid chromatography (HPLC) or gas chromatography-mass spectrometry (GC-MS) methods capable of detecting and quantifying individual cannabinoids at concentrations as low as 0.01%. Test results must be published via QR code on product packaging and reported to DSHS within 10 days of sale.

Rule 229.7 establishes civil penalties: $5,000 for a first violation involving sale of prohibited products, $15,000 for a second violation within 12 months, and $25,000 per day for continued violations after a cease-and-desist order. The rule also authorizes DSHS to suspend or revoke retail licenses and refer cases to DPS for criminal prosecution.

Criminal Penalties

Under Texas Health and Safety Code § 481.121, possession of a banned THC product is classified based on amount. Possession of less than two ounces is a Class B misdemeanor (up to 180 days in jail, $2,000 fine). Possession of two to four ounces is a Class A misdemeanor (up to one year in jail, $4,000 fine). Possession of more than four ounces triggers felony charges ranging from state jail felony to first-degree felony depending on total weight.

Possession with intent to deliver carries enhanced penalties under § 481.120. Distribution of any amount of a banned THC product is a state jail felony (180 days to two years in state jail, $10,000 fine). Distribution of more than five pounds is a second-degree felony (two to 20 years in prison, $10,000 fine).

Relationship to Federal Scheduling

The Texas ban operates independently of federal marijuana scheduling. Even if the Drug Enforcement Administration (DEA) were to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act—a proposal under review as of July 2026—Texas law would continue to prohibit delta-8 THC and other banned cannabinoids. Federal rescheduling would affect only marijuana and its derivatives; hemp-derived products would remain governed by the Farm Bill and state hemp laws.

Conversely, if the DEA were to issue a federal rule classifying delta-8 THC as a controlled substance (as the agency suggested in an August 2020 interim final rule that was never finalized), Texas's ban would align with federal law, potentially simplifying interstate enforcement but not changing the state-level prohibition already in effect.

What Remains Legal in Texas

Despite the sweeping ban on intoxicating hemp derivatives, Texas law continues to permit sale and possession of traditional CBD products, low-potency hemp flower, and participation in the state's limited medical cannabis program.

CBD Products

Cannabidiol (CBD) products derived from hemp and containing no more than 0.3% total THC remain fully legal. This includes CBD tinctures, capsules, topicals, and edibles, provided they meet testing requirements under 25 TAC § 229.5. Retailers may sell CBD products without age restrictions, though DSHS recommends voluntary 21+ policies.

The legal CBD market in Texas generated approximately $420 million in sales during 2025, according to the Hemp Business Journal, and is projected to grow as former delta-8 consumers shift to higher-dose CBD formulations. Products combining CBD with other legal hemp cannabinoids such as CBG (cannabigerol) and CBN (cannabinol) also remain permissible provided total THC stays below 0.3%.

Hemp Flower

Raw hemp flower—the dried buds of hemp plants—remains legal for sale and possession if it contains no more than 0.3% total THC and has not been enhanced with delta-8 distillate or other banned cannabinoids. Consumers may purchase and possess hemp flower for smoking, vaporization, or home extraction, though DSHS rules prohibit marketing hemp flower as a smokable product due to federal Food and Drug Administration (FDA) restrictions on inhaled CBD products.

Law enforcement faces practical challenges distinguishing legal hemp flower from illegal marijuana flower, as both are visually and aromatically identical. DPS field test kits can detect THC presence but cannot quantify concentration with sufficient precision to differentiate 0.3% hemp from 15% marijuana. This has led to continued arrests and prosecutions that are later dismissed after laboratory testing confirms legal THC levels, a pattern civil liberties organizations cite as evidence of the ban's unintended consequences.

Texas Compassionate Use Program

Texas's medical cannabis program, established by the Texas Compassionate Use Act (Health and Safety Code Chapter 169), allows qualified patients to access low-THC cannabis through licensed dispensaries. As of July 2026, the program served approximately 52,000 registered patients with qualifying conditions including epilepsy, multiple sclerosis, autism, cancer, and post-traumatic stress disorder.

The program permits cannabis products containing up to 1% THC by weight—higher than the 0.3% hemp limit but far lower than medical marijuana programs in other states. Only three licensed dispensaries operate statewide (Compassionate Cultivation in Austin, Cansortium Texas in Schulenburg, and Texas Original Compassionate Cultivation in Manchaca), creating access barriers for patients in rural areas.

Advocates have pushed to expand the program's qualifying conditions and increase the THC cap to 5%, but legislative efforts stalled in the 2025 session. The Texas Medical Association supports expansion, while law enforcement groups and some conservative legislators oppose changes, creating a political stalemate.

Market and Business Implications

The ban triggered immediate market contraction, supply chain disruption, and strategic pivots across the Texas hemp industry, with ripple effects extending to cultivators, manufacturers, distributors, and retailers.

Retail Sector Impact

An estimated 2,400 retail locations sold delta-8 THC products in Texas as of June 2026. These businesses fell into three categories: dedicated hemp shops (approximately 600 locations) that derived 70-90% of revenue from delta-8 sales; convenience stores and smoke shops (approximately 1,400 locations) where delta-8 represented 20-40% of revenue; and online retailers (approximately 400 Texas-based operations) selling nationwide.

Dedicated hemp shops faced existential threats. Green Gorilla Hemp, a Dallas-based chain with 14 locations, announced on July 10, 2026, that it would close nine stores and lay off 47 employees, retaining only locations in high-traffic areas where CBD sales could sustain operations. Owner Marcus Chen stated that delta-8 products accounted for 82% of revenue in 2025, and the company had written off $1.8 million in inventory that could not be sold legally after July 31.

Convenience stores adapted more easily, reallocating shelf space to CBD products, kratom, and nicotine alternatives. 7-Eleven corporate communications confirmed that its 1,100 Texas locations removed delta-8 products by July 25, 2026, with minimal revenue impact as the category represented less than 3% of total sales.

Manufacturing and Distribution

Texas-based hemp processors faced the most severe disruption. Approximately 85 licensed hemp manufacturers operated in the state as of early 2026, with 60% focused primarily on delta-8 production. These facilities used isomerization processes to convert CBD isolate—purchased from hemp farmers nationwide—into delta-8 distillate, which was then formulated into finished products.

Bluebird Botanicals Texas, a Houston manufacturer producing 40,000 delta-8 vape cartridges weekly, ceased operations on June 30, 2026, laying off its entire 68-person workforce. CEO Brandon Beatty stated in a June 15 press release that the company explored pivoting to CBD manufacturing but determined that market saturation and lower profit margins made the transition economically unviable. The facility's specialized isomerization equipment, valued at approximately $2.3 million, had no alternative use and was sold for scrap.

Wholesale distributors reported catastrophic inventory losses. Texas Hemp Wholesale, a San Antonio distributor supplying 340 retail accounts, reported $8.4 million in unsellable delta-8 inventory as of July 31. The company offered deep discounts to out-of-state buyers in states where delta-8 remains legal, recovering approximately 15 cents on the dollar.

Agricultural Impact

Hemp farmers experienced indirect effects. Texas cultivated approximately 4,200 acres of hemp in 2025, according to the Texas Department of Agriculture, with 70% of harvested biomass sold to processors for CBD and delta-8 production. The ban eliminated the delta-8 processing market, reducing demand for hemp biomass and depressing wholesale prices.

Wholesale CBD biomass prices in Texas fell from an average of $325 per pound in January 2026 to $180 per pound by August 2026, according to Hemp Benchmarks market data. Farmers who planted 2026 crops expecting delta-8 processor demand faced losses, with some leaving harvested hemp unharvested in fields due to prices below production costs.

Investment and Capital Flows

Venture capital investment in Texas hemp companies evaporated following HB 218's passage. PitchBook data shows that Texas hemp startups raised $47 million across 12 deals in 2024, but only $3.2 million across two deals in the first seven months of 2026—both focused on CBD brands with national distribution rather than Texas-specific retail operations.

Multi-state operators (MSOs) with hemp divisions reassessed Texas exposure. Curaleaf Holdings, which operated hemp retail locations in 14 states including Texas, announced on May 20, 2026, that it would exit the Texas market entirely, closing four locations and redirecting resources to states with more favorable regulatory environments. The company cited the ban and Texas's restrictive medical program as factors making the state unattractive for cannabis-adjacent investment.

Black Market Dynamics

Industry observers and law enforcement officials anticipated that the ban would drive some delta-8 consumers to illicit markets. The Texas Department of Public Safety reported that marijuana seizures at the Texas-Mexico border increased 18% in the first six months of 2026 compared to the same period in 2025, though officials could not definitively attribute the increase to delta-8 ban anticipation.

Online gray markets also emerged. As of mid-August 2026, multiple websites based outside Texas continued shipping delta-8 products to Texas addresses, exploiting enforcement gaps in interstate commerce. DSHS lacks jurisdiction over out-of-state retailers, and federal agencies have not prioritized enforcement of state-level hemp bans, creating a regulatory void.

What Experts Say

Public health officials, industry representatives, legal scholars, and patient advocates offered sharply divergent assessments of the ban's necessity, effectiveness, and consequences.

Dr. Peter Grinspoon, a primary care physician and cannabis specialist at Harvard Medical School, stated in a July 2026 interview with the Texas Tribune that the ban reflected "a predictable regulatory overcorrection to a legitimate but manageable public health concern." According to Grinspoon, the appropriate response to unregulated delta-8 products would have been testing requirements, potency limits, and age restrictions—not prohibition. He noted that patients using delta-8 for chronic pain would likely substitute with prescription opioids or unregulated marijuana, neither of which represented a public health improvement.

Dr. Sharon Levy, director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital, took a different view in testimony submitted to the Texas Legislature in March 2025. Levy cited data from the National Poison Data System showing a 450% increase in delta-8 THC exposure calls involving patients under 18 between 2020 and 2024, with 23% requiring hospitalization. She argued that the lack of federal oversight and state regulation created an untenable risk to minors, and that prohibition was justified until comprehensive regulatory frameworks could be established.

Paul Armentano, deputy director of NORML, characterized the ban as "prohibition by another name" in a July 28, 2026 statement. According to Armentano, Texas lawmakers used concerns about delta-8 as a pretext to maintain broader cannabis prohibition while avoiding politically difficult debates about adult-use legalization. He noted that 24 states have legalized recreational marijuana, creating a policy environment where Texas's approach appears increasingly anachronistic.

From an industry perspective, Jonathan Miller, general counsel for the U.S. Hemp Roundtable, stated in a June 2026 webinar that the Texas ban represented a "worst-case scenario" for the national hemp industry. Miller argued that the failure to distinguish between responsible hemp businesses seeking regulatory clarity and bad actors selling untested products to minors had resulted in blanket prohibition that punished compliant operators and consumers alike. He advocated for federal legislation establishing nationwide hemp product standards to prevent state-by-state fragmentation.

Legal scholars focused on federalism implications. Professor Robert Mikos of Vanderbilt Law School, an expert on marijuana federalism, noted in a July 2026 law review article that Texas's ban tested the outer boundaries of state authority under the Farm Bill. While the 2018 law explicitly preserved state regulatory power, Mikos argued that states banning hemp derivatives that meet federal THC limits could face dormant Commerce Clause challenges if their regulations discriminate against interstate commerce. The Texas Hemp Coalition's pending lawsuit raises precisely this issue.

What's Next

The Texas THC product ban's future depends on pending litigation, potential legislative amendments, federal regulatory developments, and enforcement patterns that will emerge over the next 12 to 24 months.

Legal Challenges

The Texas Hemp Coalition's lawsuit, filed July 28, 2026, in Travis County District Court, challenges HB 218 on multiple grounds. The complaint argues that the ban violates the Texas Constitution's due process protections by prohibiting naturally occurring cannabinoids without a rational basis, and that the statute's definition of "synthetically derived" is unconstitutionally vague. The coalition also asserts that the ban violates the dormant Commerce Clause by discriminating against interstate hemp commerce.

A hearing on the coalition's motion for a preliminary injunction is scheduled for September 15, 2026. If